SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q3 Trading Update

21 Oct 2021 07:00

RNS Number : 7297P
Rentokil Initial PLC
21 October 2021
 

  

 

21 October 2021

RENTOKIL INITIAL PLC (RTO) - THIRD QUARTER TRADING UPDATE

Strong momentum across our core businesses in Q3, continued good execution of M&A

 

 

(£m)

Q3 2021

Growth

AER

AER

CER

Ongoing Revenue1

761.3

0.9%

4.8%

Revenue

761.9

0.5%

4.4%

Excluding Disinfection

Ongoing Revenue1

750.2

10.2%

14.5%

Revenue

750.8

9.7%

14.0%

 

Overview of Q3 performance (at CER)

Q3 saw continued strong momentum in our core businesses with Group Ongoing Revenue, excluding disinfection services, growing by 14.5%, of which 6.7% was Organic2 and 7.8% was from acquisitions.

Pest Control delivered an excellent performance overall during the period. Despite our Australian, New Zealand, Malaysian and Indonesian operations being materially impacted by lockdowns in Q3, the category grew Ongoing Revenues by 18.3%, of which 7.5% was Organic. Ongoing Revenue in our Growth and Emerging markets grew by 18.7% and 15.6% respectively. In our North America business, a higher number of colleagues either off work with COVID-19 or self-isolating contributed to some labour shortages in the quarter. Despite this, our Pest Control business in North America continued to demonstrate very strong momentum, growing revenues by 24.6%, 10.1% Organic.

Our Core Hygiene business, excluding disinfection, delivered a 6.4% increase in Ongoing Revenue (4.7% Organic), reflecting good performances in the UK, Europe and Latin America but held back, as with Pest Control, by significant challenges associated with lockdowns and movement restrictions in Australia, New Zealand, Indonesia and Malaysia.

Sales from disinfection services have tapered in line with our expectations at £11.4m (Q1: £75.7m, Q2: £22.6m), a decline of £62.1m on this time last year. We are maintaining our guidance for disinfection revenues in H2 to be within the range of £10m to £20m.

Ongoing Revenue in our Protect & Enhance category grew by 6.2% (5.5% Organic), reflecting further recovery in our France Workwear, Ambius, UK Property Care and Dental Hygiene services businesses.

New category structure - Hygiene & Wellbeing

At our Capital Markets Day on 28 September, we announced that in response to the increasing importance of hygiene and wellbeing services, we are expanding our Hygiene category with effect from 1 January 2022. The enlarged category, called Hygiene & Wellbeing, will comprise our current Hygiene operations together with our Ambius, Dental Hygiene and Cleanroom services operations, previously part of our Protect & Enhance category. Adopting the new category structure in Q3 would give organic growth in Hygiene & Wellbeing of 6.6%.

M&A

​We completed nine acquisitions in Q3: seven in Pest Control; one in Hygiene; and the previously announced transaction with Boecker, which completed on 3 August and which offers both Pest Control and Hygiene services. As a result, we have acquired businesses with operations in Australia, Chile, Colombia, Guadeloupe, Lebanon, Saudi Arabia, United Arab Emirates and the US, as well as interests in affiliated businesses in Kuwait, Qatar and Nigeria. Together, these have combined annualised revenues in the year prior to acquisition of c.£48m. Q2's excellent momentum has been maintained in Q3 and also into Q4, and our anticipated full year expenditure on M&A remains in the region of at least £450m to £500m, as previously guided.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"We have delivered a strong performance from our core businesses in the quarter and are confident of sustaining this momentum for the remainder of the year. Assuming no further significant deterioration in trading conditions arising from the pandemic, our performance in Q3 - combined with further progress in our value-creating M&A programme - means we remain on track to deliver a full year performance in line with the guidance given at our interim results in July."

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978199

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

AER - actual exchange rates; CER - constant 2020 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPPGUAUUPGGQU
Date   Source Headline
19th Jul 20177:00 amRNSAppointment of Non-Executive Director
30th Jun 20178:33 amRNSCompletion of Joint Venture with Haniel
27th Jun 20175:21 pmRNSHolding(s) in Company
26th Jun 20174:54 pmRNSHolding(s) in Company
8th Jun 201711:40 amRNSFurther re Joint Venture with Haniel
7th Jun 20179:41 amRNSDirector Declaration
17th May 20175:02 pmRNSHolding(s) in Company
10th May 20174:31 pmRNSResult of AGM
10th May 20174:03 pmRNSHolding(s) in Company
10th May 201711:49 amRNSAppointment of Senior Independent Director
9th May 20175:51 pmRNSHolding(s) in Company
4th May 20174:44 pmRNSDirector/PDMR Shareholding
26th Apr 20174:27 pmRNSDirector/PDMR Shareholding
25th Apr 20175:58 pmRNSDirector/PDMR Shareholding
21st Apr 20177:00 amRNSRentokil awarded Queen's Award for Enterprise
19th Apr 20177:00 amRNSQ1 Trading Update
5th Apr 201710:43 amRNSAnnual Financial Report
31st Mar 20174:18 pmRNSTotal Voting Rights
30th Mar 20173:25 pmRNSBlock listing Interim Review
22nd Mar 20176:10 pmRNSHolding(s) in Company
9th Mar 20173:06 pmRNSAdditional Listing
28th Feb 20177:00 amRNSRentokil - Leading Pest Control Company in India
24th Feb 20172:37 pmRNSHolding(s) in Company
23rd Feb 20177:00 amRNSFinal Results
7th Feb 20177:00 amRNSAcquisition of Allgood Pest Solutions
29th Dec 20164:30 pmRNSDirector/PDMR Shareholding
16th Dec 20162:59 pmRNSHolding(s) in Company
16th Dec 20162:02 pmRNSHolding(s) in Company
16th Dec 20167:00 amRNSJoint venture with Haniel
7th Dec 20165:47 pmRNSHolding(s) in Company
7th Dec 20167:00 amRNSHolding(s) in Company
18th Nov 20161:15 pmRNSDirector Declaration
11th Nov 20165:30 pmRNSHolding(s) in Company
11th Nov 20165:10 pmRNSTotal Voting Rights
3rd Nov 20161:01 pmRNSDirector Declaration
19th Oct 20167:00 amRNSQ3 Trading Update
6th Oct 20162:58 pmRNSAdditional Listing
6th Oct 201612:31 pmRNSDirector Declaration
4th Oct 20169:49 amRNSDirector Declaration
30th Sep 20162:10 pmRNSTotal Voting Rights
29th Sep 20167:00 amRNSAdditional Listing
26th Sep 20164:48 pmRNSDirector/PDMR Shareholding
22nd Aug 20164:56 pmRNSHolding(s) in Company
28th Jul 20167:00 amRNSHalf Yearly Report
27th Jul 20167:00 amRNSCollaboration with Google and PA Consulting Group
7th Jul 20167:00 amRNSAcquisition, CDC Contract Win and Trading Update
29th Jun 20167:00 amRNSDirectorate Change
29th Jun 20167:00 amRNSDirector/PDMR Shareholding
22nd Jun 20165:27 pmRNSHolding(s) in Company
17th May 20165:06 pmRNSDirector/PDMR Shareholding - Replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.